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Abstract 
Background: Few validated biomarker or clinical score combinations exist which can discriminate between cases of 
infection and other non‑infectious conditions following activation of an in‑hospital sepsis code, as well as provide an 
accurate severity assessment of the corresponding host response. This study aimed to identify suitable blood bio‑
marker (MR‑proADM, PCT, CRP and lactate) or clinical score (SOFA and APACHE II) combinations to address this unmet 
clinical need.
Methods: A prospective, observational study of patients activating the Vall d’Hebron University Hospital sepsis code 
(ISC) within the emergency department (ED), hospital wards and intensive care unit (ICU). Area under the receiver 
operating characteristic (AUROC) curves, logistic and Cox regression analysis were used to assess performance.
Results: 148 patients fulfilled the Vall d’Hebron ISC criteria, of which 130 (87.8%) were retrospectively found to have 
a confirmed diagnosis of infection. Both PCT and MR‑proADM had a moderate‑to‑high performance in discriminat‑
ing between infected and non‑infected patients following ISC activation, although the optimal PCT cut‑off varied 
significantly across departments. Similarly, MR‑proADM and SOFA performed well in predicting 28‑ and 90‑day mor‑
tality within the total infected patient population, as well as within patients presenting with a community‑acquired 
infection or following a medical emergency or prior surgical procedure. Importantly, MR‑proADM also showed a high 
association with the requirement for ICU admission after ED presentation [OR (95% CI) 8.18 (1.75–28.33)] or during 
treatment on the ward [OR (95% CI) 3.64 (1.43–9.29)], although the predictive performance of all biomarkers and clini‑
cal scores diminished between both settings.
Conclusions: Results suggest that the individual use of PCT and MR‑proADM might help to accurately identify 
patients with infection and assess the overall severity of the host response, respectively. In addition, the use of 
MR‑proADM could accurately identify patients requiring admission onto the ICU, irrespective of whether patients 
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Introduction
An early diagnosis of sepsis, irrespective of hospitalisa-
tion setting, is crucial in order to provide a rapid and 
appropriate therapeutic response. This, however, may 
be complicated by the complex and heterogeneous host 
response to infection, as well as the high level of patient 
heterogeneity between departments [1].
A standardised set of defined criteria to aid in the 
early identification of sepsis therefore remains elusive, 
despite the established use of specific parameters in 
conditions such as myocardial infarction and pulmo-
nary embolism [2]. Furthermore, the poor acceptance 
of previous [3] and current [4, 5] definitions has led 
to significant debate concerning the most appropriate 
clinical criteria required to make an accurate diagnosis. 
Differential presenting signs, symptoms and severities 
at each stage of hospitalisation, as well as prior surgical 
history and the setting of the original infectious insult, 
significantly exacerbate this already complex diagnosis.
The construction and validation of new parameters 
to aid in the early diagnosis and severity assessment of 
sepsis patients is therefore crucial. The recent develop-
ment of tools such as the quick Sequential Organ Fail-
ure Assessment (qSOFA) score to screen patients at risk 
of a poor outcome has resulted in additional param-
eters becoming available to the treating clinician [6]; 
however, significant inherent and kinetical limitations 
make its implementation problematic [7–9]. The use of 
a panel of blood biomarkers, however, may provide a 
more elegant solution. Whilst measurement of individ-
ual biomarkers to concurrently discriminate between 
infectious and non-infectious patients and provide an 
accurate assessment of disease severity is highly desir-
able [10], no such biomarker appears to have a high 
enough accuracy to fulfil both clinical requirements. 
Accordingly, both requirements should be considered 
separately.
The use of procalcitonin (PCT) and C-reactive pro-
tein (CRP) to discriminate between infectious and non-
infectious cases is well documented [11–15], despite 
neither biomarker being well-established in the field of 
emergency medicine or on the medical ward. Further-
more, neither biomarkers exhibit a robust performance 
in terms of mortality prediction or in the identification 
of patients requiring intensive care (ICU) admission. 
Conversely, the novel blood biomarker, mid-regional 
proadrenomedullin (MR-proADM) has been shown 
to be elevated in the early stages of infectious disease 
progression in the emergency department (ED) [16], 
after severe burn injury on a medical ward [17], and in 
critically ill sepsis patients with decreasing PCT con-
centrations [1] who may require renal replacement 
therapy (RRT) [18], or are likely to progress towards 
multiple organ failure [19].
This study therefore aimed to investigate the perfor-
mance of each biomarker (MR-proADM, PCT, CRP and 
lactate) and clinical score (SOFA and APACHE II) in 
patients fulfilling the criteria for the Vall d’Hebron Uni-
versity in-hospital sepsis code (ISC) in order to: (1) dis-
criminate between infected and non-infected patients; 
(2) assess infection severity according to 28- and 90-day 
mortality prediction, and (3) identify patients presenting 
to the ED or undergoing treatment on a medical/surgical 
ward who require subsequent ICU admission.
Methods
Study design and ethical approval
This single-centre, observational study prospectively 
enrolled consecutive patients across all hospital depart-
ments (ED, ward and ICU) who met the criteria for the 
activation of the Vall d’Hebron University Hospital in-
hospital sepsis code (ISC) [20] between November 2016 
and August 2017. The study protocol was approved by 
the Clinical Research Ethics Committee of Vall d’Hebron 
University Hospital (PR(AG)333/2016) without the need 
for informed consent, and was performed in accordance 
with the ethical standards laid down in the 1964 Declara-
tion of Helsinki and its later amendments.
Inclusion and exclusion criteria
Inclusion criteria comprised adult patients ≥ 18 years of 
age presenting with either a suspected or documented 
infection with the presence of at least one of the two fol-
lowing sets of variables, as outlined by the Vall d’Hebron 
University Hospital in-hospital sepsis code (ISC) [20]: 
(1) an acute alteration in the level of consciousness not 
explained by other clinical conditions, or (2) the presence 
of hyperthermia (axillary temperature > 38.3 °C) or hypo-
thermia (axillary temperature < 36.0  °C), and/or tachy-
cardia (> 110 beats per minute), tachypnea (> 30 breaths 
per minute) or desaturation  (SpO2 < 90%), as well as arte-
rial hypotension (systolic arterial pressure < 90  mmHg 
or mean arterial pressure < 65  mmHg, or a decrease of 
> 40 mmHg of baseline systolic arterial pressure). Exclu-
sion criteria included non-adult patients, pregnancy, or 
patients where no blood sample could be obtained.
presented to the ED or were undergoing treatment on the ward. Initial measurement of both biomarkers might there‑
fore facilitate early treatment strategies following activation of an in‑hospital sepsis code.
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Study endpoints and analytical aims
Study endpoints and analytical aims were defined as fol-
lows. Infection identification: either proven infection 
resulting from a positive blood culture or microbial iden-
tification, or a final clinical diagnosis of infection. 28- and 
90-day mortality: all-cause mortality within either 28 or 
90 days following enrolment. Community-acquired infec-
tion: infectious insult developed outside the hospital 
within the community. Hospital-acquired infection: infec-
tious insult developed whilst a patient was hospitalised 
for a previously non-infectious complaint. ICU admis-
sion: admission onto either a medical or surgical inten-
sive care unit within 28 days of sepsis code activation.
Data collection and biomarker measurements
Patient comorbidities and demographics were subse-
quently noted upon sepsis code activation, as well as data 
concerning triage, routine laboratory values, microbiol-
ogy testing and final clinical diagnosis. Clinical scores 
(APACHE II and SOFA) were retrospectively calculated 
whenever possible upon enrolment. The following bio-
marker measurements were performed as standard: 
PCT using a chemiluminescent immunoassay (CLIA), 
CRP using an immuno-turbidimetric test, and L-lactate 
using an enzymatic colour test. MR-proADM was retro-
spectively analysed following blood sampling through a 
central catheter, and stored at − 80 °C until batch analy-
sis using TRACE technology (time-resolved amplified 
cryptate emission, KRYPTOR platform, Thermo Fisher). 
Results were unavailable to the treatment physician 
throughout patient enrolment and hospitalisation.
Statistical analysis
Data were either reported using the mean (standard 
deviation) for symmetrically distributed variables, or 
the median [first quartile  −  third quartile] for vari-
ables showing a skewed distribution. Demographic and 
clinical characteristics between surviving and non-
surviving patients up to 28  days following sepsis code 
activation were assessed using the Chi-square (χ2) test 
for categorical variables, Student’s t test for age, and the 
Mann–Whitney U test for all other continuous vari-
ables. Area under the receiver operating characteristic 
(AUROC) curves were used to identify the biomarker 
or clinical score with the greatest predictive value for 
each endpoint, with 95% confidence intervals (95% CI) 
compared to determine significance. Youden’s criterion 
established optimal cut-off values with corresponding 
sensitivity and specificity values. Univariate and multi-
variate Cox regression models assessed the association 
with survival time (censored at 28 days following sepsis 
code activation), with potential confounding variables 
selected based on a univariate analysis (p-value < 0.005 
after applying a Bonferroni correction), and subse-
quently included in a multivariate analysis. Results were 
either presented as the hazard (HR) or odds ratio (OR) 
per 1 interquartile-range increase for mortality predic-
tion and ICU admission, respectively, with correspond-
ing 95% confidence intervals. Previously established 
[16] biomarker cut-offs for 28-day mortality prediction 
were further analysed within this dataset, and mortality 
rates in patient subgroups with high biomarker values 
compared to those with low values. All data were ana-
lysed using the statistics software R (version 3.1.2).
Results
Patient characteristics
A total of 150 patients were identified and enrolled 
after activation of the sepsis code (sepsis code group), 
comprising 43 (29.1%) presenting to the emergency 
department (ED), 70 (47.3%) already undergoing treat-
ment on a medical or surgical ward, and 35 (23.6%) 
already present on the intensive care unit (ICU). 2 
patients were removed from the analysis due to a lack 
of blood sample.
Infection identification following sepsis code activation
Based on final clinical diagnosis, a total of 130 (87.8%) 
infected (sepsis code infected group) and 18 (12.2%) non-
infected patients (sepsis code non-infected group) could 
be retrospectively identified following initial sepsis code 
activation. Patient characteristics of the infected popula-
tion are presented in Table 1. PCT was found to have a 
high discriminatory performance (Fig. 1a), with an opti-
mal cut-off of 2.02  ng/mL (sensitivity and specificity: 
0.73 and 0.78). This cut-off, however, varied considerably 
depending on the location of sepsis code activation, with 
an optimal cut-off of 0.37 ng/mL (sensitivity and specific-
ity: 0.86 and 0.75) in the ED, 1.91 ng/mL (sensitivity and 
specificity: 0.77 and 0.86) on the ward and 2.02  mg/mL 
(sensitivity and specificity: 0.79 and 0.71) on the ICU.
In the sepsis code infected group, a positive blood cul-
ture rate was obtained in 54 (42.2%) cases, with a greater 
prevalence of Gram-positive as opposed to Gram-nega-
tive infections (N = 34; 26.2% vs. N = 17; 13.1%, p < 0.01). 
A comparison of biomarker and clinical score perfor-
mance found that PCT had a moderate performance in 
predicting the likelihood of a positive culture (Fig.  1b). 
The addition of further biomarkers or clinical scores to 
initial PCT measurements resulted in no significant 
increase in discriminatory (infected vs. non-infected 
patients) or predictive (positive vs. negative blood cul-
ture) performance.
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Table 1 Clinical patient characteristics upon  activation of  the  sepsis code with  respect to  the  total infected patient 
population and subsequent 28-day mortality
Patient population (N = 130) Survivors (N = 102) Non-survivors (N = 28) p-value
Age (years) (mean, S.D.) 63.1 (15.2) 62.3 (15.2) 66.1 (15.0) 0.205
Male gender (N, %) 83 (63.8%) 61 (59.8%) 22 (78.6%) 0.348
Infection characterisation
 Infection no SIRS (N,  %) 7 (5.4%) 6 (5.9%) 1 (3.6%) 0.623
 Severe sepsis (N,  %) 41 (31.8%) 37 (36.3%) 4 (14.3%) 0.028
 Septic shock (N,  %) 82 (63.1%) 59 (57.8%) 23 (82.1%) 0.031
 Sepsis‑2 (N,  %) 122 (93.8%) 95 (93.1%) 27 (96.4%) 0.814
 Sepsis‑3 (N,  %) 116 (89.2%) 88 (86.3%) 28 (100.0%) 0.157
Location of sepsis code activation
 Emergency department (N,  %) 39 (30.0%) 33 (32.4%) 6 (21.4%) 0.568
 Ward (N,  %) 63 (48.5%) 47 (46.1%) 16 (57.1%) 0.729
 ICU (N,  %) 28 (21.5%) 22 (21.6%) 6 (21.4) 0.839
 Surgical admissions (N,  %) 47 (36.2%) 37 (36.3%) 10 (35.7%) 0.487
 Medical admissions (N,  %) 83 (63.8%) 65 (63.7%) 18 (64.3%) 0.487
 ICU length of stay (days) (median, IQR) 6 [2–15] 5 [2–11] 12 [3–24] 0.093
 Hospital length of stay (days) (median, IQR) 16.5 [8–31] 17 [8–33] 16 [5.5–27] 0.298
Life supporting and intensive care therapies
 Vasopressors (N,  %) 67 (51.5%) 52 (40.0%) 15 (53.6%) 0.106
 Renal replacement therapy (N,  %) 15 (11.5%) 8 (6.2%) 7 (25.0%) 0.009
 Mechanical ventilation (N, %) 44 (33.8%) 30 (23.1%) 14 (50.0%) 0.011
 Mechanical ventilation duration (days) 7 [3–16.25] 5 [3–17.5] 10 [4.5–14.75] 0.081
 High‑flow nasal cannula use (N, %) 19 (14.6%) 16 (15.7%) 3 (10.7%) 0.386
Pre‑existing comorbidities
 Cardiopathy (N, %) 24 (18.5%) 16 (15.7%) 8 (28.6%) 0.120
 Chronic kidney disease (N, %) 19 (14.6%) 14 (13.7%) 5 (17.6%) 0.584
 COPD (N, %) 19 (14.6%) 10 (9.8%) 9 (32.1%) 0.003
 Immunosuppression (N, %) 63 (48.5%) 44 (43.1%) 19 (67.9%) 0.020
 Liver cirrhosis (N, %) 3 (2.3%) 1 (1.0%) 2 (7.1%) 0.054
Microbiology
 Positive blood culture (N, %) 54 (41.5%) 40 (39.2%) 14 (50.0%) 0.238
 Gram positive (N, %) 34 (26.2%) 24 (23.5%) 10 (35.7%) 0.895
 Gram negative (N, %) 17 (13.1%) 13 (12.7%) 4 (14.3%) 0.797
 Fungal (N, %) 2 (1.5%) 1 (1.0%) 2 (7.1%) 0.529
Origin of infection
 Abdominal (N, %) 41 (31.5%) 35 (34.3%) 6 (21.4%) 0.194
 Bacteria—primary (N, %) 4 (3.1%) 3 (2.9%) 1 (3.6%) 0.864
 Catheter‑related (N,  %) 8 (6.2%) 5 (4.9%) 3 (10.7%) 0.257
 Central nervous system (N, %) 2 (1.5%) 1 (1.0%) 1 (3.6%) 0.324
 Respiratory (N, %) 34 (26.2%) 25 (24.5%) 9 (32.1%) 0.416
 Soft‑tissue (N, %) 4 (3.1%) 4 (3.9%) 0 (0.0%) 0.287
 Urinary (N, %) 30 (23.1%) 25 (24.5%) 5 (17.9%) 0.459
 Unknown (N, %) 3 (2.3%) 1 (1.0%) 2 (7.1%) 0.054
 Other (N, %) 4 (3.1%) 3 (2.9%) 1 (3.6%) 0.864
Source control
 Focus cleaning (N,  %) 34 (26.2%) 28 (27.5%) 6 (21.4%) 0.521
 Drainage (N, %) 8 (6.2%) 6 (5.9%) 2 (7.1%) 0.806
 Surgery (N, %) 23 (17.7%) 20 (19.6%) 3 (10.7%) 0.275
Biomarker and severity scores
 MR‑proADM (nmol/L) (median, IQR) 3.54 [1.89–6.69] 3.18 [1.73–5.64] 5.69 [3.98–13.43] < 0.001
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28- and 90-day mortality prediction
The 28-day all-cause mortality rate within the sepsis 
code infected group was 21.5% (N = 28), with a higher 
mortality rate in patients enrolled whilst on the ward 
(N = 16; 25.4%) and ICU (N = 6; 21.4%) as opposed to 
in the ED (N = 6; 15.4%; Table 1). The 90-day all-cause 
mortality rate was 24.6% (N = 32). In both cases, MR-
proADM, lactate and SOFA were all significantly ele-
vated in non-surviving as opposed to surviving patients 
(p < 0.01), whereas no significant differences were found 
in PCT, CRP or APACHE II values.
Data are presented as absolute numbers with percentages in brackets, indicating the proportion of surviving and non-surviving patients at 28 days. APACHE II Acute 
Physiological and Chronic Health Evaluation II score, COPD chronic obstructive pulmonary disease, CRP C-reactive protein, ICU intensive care unit, IQR interquartile 
range, MR-proADM mid-regional proadrenomedullin, N number, PCT procalcitonin, SOFA Sequential Organ Failure Assessment score
Table 1 (continued)
Patient population (N = 130) Survivors (N = 102) Non-survivors (N = 28) p-value
 PCT (ng/mL) (median, IQR) 7.05 [1.46–28.8] 7.85 [1.61–29.13] 4.94 [1.25–29.86] 0.654
 Lactate (mmol/L) (median, IQR) 2.65 [1.70–4.57] 2.50 [1.60–3.75] 4.1 [2.0–8.10] 0.005
 CRP (mg/L) (median, IQR) 17.78 [11.03–27.88] 17.48 [10.83–27.60] 23.14 [12.86–30.80] 0.322
 SOFA (points) (mean, S.D.) 6.39 (3.46) 5.74 (3.11) 8.65 (3.70) < 0.001
 APACHE II (points) (mean, S.D.) 21.98 (7.22) 21.63 (7.58) 23.13 (6.02) 0.783
Fig. 1 AUROC and univariate analysis for a discriminating between patients with a final diagnosis of infection from those where no infection 
was found, after activation of an in‑hospital sepsis code, and b prediction of a positive blood culture in patients with a final diagnosis of infection. 
APACHE II Acute Physiological and Chronic Health Evaluation II score, AUROC area under the receiver operating characteristic curve, CI confidence 
interval, CRP C‑reactive protein, HR hazard ratio, IQR interquartile range, LR likelihood ratio, MR‑proADM: mid‑regional proadrenomedullin, N number, 
PCT procalcitonin, SOFA Sequential Organ Failure Assessment score
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AUROC analysis found that MR-proADM performed 
well in predicting 28-day mortality, followed by SOFA 
and lactate, with an optimal cut-off of 4.28 nmol/L (sensi-
tivity and specificity: 0.76 and 0.65). No significant asso-
ciation was observed with either PCT, CRP or APACHE 
II (Fig.  2). Similar findings were observed in both the 
univariate Cox regression analysis and after adjusting for 
the influence of existing chronic obstructive pulmonary 
disease (COPD), which was the only pre-existing vari-
able found to significantly influence mortality prediction. 
The addition of PCT to MR-proADM measurements fur-
ther improved predictive performance [HR (95% CI) 7.5 
(3.7–15.2)], greater than any other biomarker or clinical 
score combination. Similar results were also obtained 
for 90-day mortality prediction, with a moderate 
performance found using MR-proADM, followed by 
SOFA and lactate. The influence of existing COPD had 
little impact on predictive performance, whilst the addi-
tion of PCT to MR-proADM resulted in the greatest 
increase in predictive performance [HR (95% CI) 5.7 
(3.0–10.9)]. Interestingly, no increase in performance was 
found for the combination of PCT with either SOFA or 
lactate measurements [HR (95% CI) 2.9 (1.9–4.6) and 2.1 
(1.3–3.2)], respectively).
Using an MR-proADM cut-off of 1.54  nmol/L within 
the infected patient population, 108 (83.1%) patients 
were found to have values equal to or exceeding this 
cut-off, with a corresponding mortality rate of 24.1% 
(N = 26). In comparison, patients with MR-proADM 
values < 1.54  nmol/L (N = 22, 16.9%) had a significantly 
Fig. 2 AUROC, univariate and bivariate analysis for the prediction of 28‑day a and 90‑day b mortality for each biomarker and clinical score. APACHE 
II Acute Physiological and Chronic Health Evaluation II score, AUROC area under the receiver operating characteristic curve, CI confidence interval, 
CRP C‑reactive protein, HR hazard ratio, IQR interquartile range, LR likelihood ratio, MR‑proADM mid‑regional proadrenomedullin, N number, PCT 
procalcitonin, SOFA Sequential Organ Failure Assessment score
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(p < 0.01) lower mortality rate of 13.6% (N = 3). No patient 
died with an MR-proADN value of < 0.88 nmol/L. Only 6 
(4.6%) patients were found to have PCT concentrations 
< 0.25 μg/mL, of which one died within 28 days.
Mortality prediction based on location of infection 
development and reason for patient admission
Subgroup analysis found that a total of 67 (51.5%) 
patients developed an infection in the community and 
were subsequently hospitalised, compared to 48 (36.9%) 
patients where the infection was acquired during hos-
pitalisation despite being admitted for a non-infectious 
related condition. The 28-day mortality rates of both 
groups were, however, similar (N = 15; 22.4% vs. N = 12; 
25.0%). Likewise, 47 (36.2%) patients were identified 
using the sepsis code following a surgical procedure, as 
opposed to 83 (63.8%) patients presenting with a medi-
cal complaint, again with similar 28-day mortality rates 
between groups (N = 10; 21.3% vs. N = 18; 21.7%).
AUROC and Cox regression analysis found that MR-
proADM had a high predictive value in patients with 
community-acquired infections, followed by SOFA and 
lactate (Table 2), which could be further increased after 
the addition of PCT [HR (95% CI) 10.0 (3.6–27.5)]. The 
optimal MR-proADM cut-off was 3.67  nmol/L, with a 
sensitivity and specificity of 0.93 and 0.52, respectively. 
Conversely, the SOFA score had high predictive per-
formance in patients with hospital-acquired infections 
(Table 2). Interestingly, the combination of MR-proADM 
with APACHE II resulted in the largest increase in pre-
dictive value [HR (95% CI) 7.9 (1.5–41.1)], whereas 
the addition of PCT to MR-proADM only resulted in a 
small overall additive effect. Similarly, AUROC and Cox 
regression analysis found that MR-proADM had a mod-
erate-to-high predictive value within both medical and 
surgical patient subgroups, followed by SOFA and lac-
tate (Table 3). The combination of SOFA and APACHE II 
scores resulted in the greatest predictive performance in 
the surgical cohort [HR (95% CI) 9.36 (2.13–4.17)], com-
pared to the combination of MR-proADM and PCT in 
the medical cohort [HR (95% CI) 9.30 (3.89–22.25)].
Intensive care unit admission after sepsis code activation
Finally, biomarker and clinical score performance was 
compared in order to predict admission to both the sur-
gical and medical intensive care units. Activation of the 
sepsis code in both the ED and wards resulted in a high 
rate of admission on the same or subsequent day, with 
a total of 16 (41.0%) patients transferred from the ED 
and 28 (45.9%) patients transferred from the ward. MR-
proADM showed a moderate-to-high predictive value in 
both settings, with similar results also found after univar-
iate logistic regression (Table 4).
Discussion
This study compared the performance of a number of 
clinical severity scores, conventional and novel biomark-
ers following activation of an in-hospital sepsis code, in 
order to identify cases of infection and assess the severity 
of corresponding host response. Results found that the 
use of PCT to discriminate between sepsis code infected 
group and sepsis code non-infected group, and MR-
proADM to identify disease severity irrespective of the 
location of infectious insult, had the greatest accuracy in 
Table 2 28-day mortality prediction in patients with either community or hospital-acquired infections
APACHE II Acute Physiological and Chronic Health Evaluation II score, AUROC area under the receiver operating characteristic curve, CI confidence interval, 
CRP C-reactive protein, HR hazard ratio, IQR interquartile range, LR likelihood ratio of the χ2 test, MR-proADM mid-regional proadrenomedullin, N number, PCT 
procalcitonin, SOFA Sequential Organ Failure Assessment score
Biomarker 
or clinical score
Patients (N) Events (N) AUROC Univariate Bivariate
LR χ2 HR IQR [95% CI] LR χ2 HR IQR [95% CI]
Community MR‑proADM 67 15 0.76 [0.64–0.89] 13.08 4.60 [1.95–10.83] 14.52 4.88 [1.96–12.14]
PCT 65 15 0.54 [0.36–0.71] 0.09 0.89 [0.43–1.85] 1.64 0.89 [0.43–1.85]
CRP 66 15 0.57 [0.40–0.74] 0.48 1.28 [0.62–2.63] 2.30 1.32 [0.62–2.80]
Lactate 60 14 0.71 [0.53–0.89] 10.03 3.44 [1.59–7.45] 10.61 3.09 [1.40–6.83]
APACHE II 33 8 0.70 [0.50–0.90] 2.10 2.07 [0.77–5.55] 2.79 2.14 [0.76–6.03]
SOFA 67 15 0.73 [0.57–0.88] 8.93 2.85 [1.39–5.85] 11.16 3.01 [1.44–6.28]
Hospital MR‑proADM 48 11 0.66 [0.45–0.88] 5.59 3.15 [1.19–8.37] 5.70 3.32 [1.19–9.25]
PCT 48 11 0.46 [0.27–0.65] 0.03 0.91 [0.30–2.77] 0.19 0.88 [0.29–2.70]
CRP 48 11 0.53 [0.32–0.73] 0.52 1.20 [0.70–2.07] 0.61 1.19 [0.69–2.06]
Lactate 43 10 0.58 [0.35–0.81] 0.87 1.40 [0.70–2.77] 0.87 1.40 [0.70–2.77]
APACHE II 25 6 0.63 [0.37–0.89] 0.85 0.61 [0.21–1.74] 1.18 0.58 [0.19–1.75]
SOFA 48 11 0.78 [0.61–0.95] 12.12 3.60 [1.70–7.59] 12.18 3.58 [1.70–7.55]
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fulfilling both criteria. Interestingly, MR-proADM was 
also the most accurate parameter in identifying patients 
presenting to the ED or receiving treatment on a medi-
cal ward who subsequently required immediate ICU 
admission.
The use of clinical or laboratory parameters which are 
significantly increased in the early stages of the infectious 
cascade may allow more appropriate treatment strate-
gies to be initiated upon initial suspicion of infection, 
thus minimising the risk of patients being either under- 
or over-treated—both of which may result in undesir-
able consequences [21]. To this extent, the use of blood 
biomarkers may provide an easy and rapid source of clin-
ical information with which to inform and help develop 
clinical strategies. Of these biomarkers, PCT has been 
studied extensively in both the ED and ICU [12–15, 22–
24], with routine use in the ICU especially widespread. 
Conversely, novel biomarkers such as MR-proADM 
remain poorly understood, despite a number of recent 
studies [16, 18, 19, 25]. Furthermore, biomarker perfor-
mance may vary extensively depending on whether the 
infection had developed in the community or during hos-
pitalisation. Hence a key aim of this study focused on the 
comparison of biomarker and clinical score performance 
Table 3 28-day mortality prediction in patients enrolled following either surgical or medical complaints
APACHE II Acute Physiological and Chronic Health Evaluation II score, AUROC area under the receiver operating characteristic curve, CI confidence interval, 
CRP C-reactive protein, HR hazard ratio, IQR interquartile range, LR likelihood ratio of the χ2 test, MR-proADM mid-regional proadrenomedullin, N number, PCT 
procalcitonin, SOFA Sequential Organ Failure Assessment score
Biomarker 
or clinical score
Patients (N) Events (N) AUROC Univariate Bivariate
LR χ2 HR IQR [95% CI] LR χ2 HR IQR [95% CI]
Surgical MR‑proADM 47 10 0.80 [0.66–0.94] 9.03 6.53 [1.65–25.88] 10.40 6.34 [1.84–41.04]
PCT 47 10 0.47 [0.26–0.68] 0.34 1.39 [0.46–4.21] 0.68 1.56 [0.48–5.10]
CRP 47 10 0.59 [0.38–0.79] 0.37 1.24 [0.60–2.58] 0.55 1.26 [0.60–2.63]
Lactate 44 8 0.73 [0.49–0.97] 3.97 2.72 [1.00–7.39] 4.06 2.65 [0.98–7.20]
APACHE II 29 7 0.53 [0.29–0.77] 0.01 1.05 [0.39–2.80] 0.78 0.86 [0.29–2.53]
SOFA 47 10 0.74 [0.56–0.92] 10.86 5.05 [1.82–14.02] 11.12 5.55 [1.87–16.46]
Medical MR‑proADM 83 18 0.72 [0.57–0.87] 15.05 3.84 [1.96–7.54] 16.32 3.87 [1.90–7.86]
PCT 80 18 0.55 [0.40–0.71] 0.10 0.89 [0.44–1.79[ 2.89 0.90 [0.45–1.80]
CRP 82 18 0.46 [0.30–0.61] 0.63 1.23 [0.71–2.15] 3.49 1.27 [0.70–2.29]
Lactate 72 18 0.66 [0.51–0.82] 6.43 2.06 [1.21–3.51] 7.84 1.99 [1.14–3.46]
APACHE II 35 7 0.59 [0.34–0.82] 0.20 1.28 [0.44–1.79] 0.43 1.17 [0.38–3.59]
SOFA 83 18 0.71 [0.57–0.86] 16.32 3.87 [1.90–7.86] 13.33 2.50 [1.43–4.36]
Table 4 Intensive (ICU) and surgical intensive (ICU) care unit admission from the emergency department and ward
APACHE II Acute Physiological and Chronic Health Evaluation II score, AUROC area under the receiver operating characteristic curve, CI confidence interval, CRP 
C-reactive protein, IQR interquartile range, LR likelihood ratio of the χ2 test, MR-proADM mid-regional proadrenomedullin, N number, OR odds ratio, PCT procalcitonin, 
SOFA Sequential Organ Failure Assessment score
Biomarker 
or clinical score
Patients (N) Events (N) AUROC Univariate
LR χ2 OR IQR [95% CI]
Emergency department MR‑proADM 39 16 0.80 [0.66–0.94] 10.55 8.18 [1.75–28.33]
PCT 37 16 0.74 [0.57–0.90] 7.18 3.59 [1.27–10.12]
CRP 38 16 0.64 [0.46–0.82] 2.83 1.98 [0.85–4.60]
Lactate 33 14 0.45 [0.24–0.65] 0.72 0.60 [0.18–1.99]
APACHE II 16 14 0.63 [0.33–0.92] 0.21 1.63 [0.20–13.47]
SOFA 39 16 0.78 [0.64–0.93] 10.21 5.04 [1.59–15.99]
Ward admission MR‑proADM 63 28 0.72 [0.64–0.79] 10.1 3.64 [1.43–9.29]
PCT 63 28 0.59 [0.46–0.72] 3.5 1.85 [0.93–3.69]
CRP 63 28 0.57 [0.41–0.65] 0.8 0.76 [0.41–1.41]
Lactate 63 28 0.57 [0.44–0.70] 1.7 1.49 [0.81–2.74]
APACHE II 20 16 0.69 [0.40–0.77] 1.3 0.38 [0.06–2.27]
SOFA 63 28 0.64 [0.49–0.75] 3.8 2.03 [0.97–4.24]
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according to the location of initial infection development, 
following activation of an in-hospital sepsis code.
Based on recent publications, the use of MR-proADM 
was of especial interest within our investigation, with 
previous studies showing elevated concentrations 
resulting from increased levels of microcirculatory and 
endothelial damage, resulting in the early stages of subse-
quent organ dysfunction [26–29]. The use of a biomarker 
to identify developing microcirculatory damage may con-
tribute significant information following the activation of 
a local, in-hospital sepsis code.
Accordingly, results from this investigation potentially 
indicate two clinically important uses of MR-proADM 
following sepsis code activation. Firstly, MR-proADM 
may be used as a tool to aid in the early identification of 
disease severity, irrespective of medical setting or prior 
surgical history. Secondly, it may also be used to aid clini-
cal decision-making in assessing ICU requirement within 
the ED or on a medical ward.
This study found that MR-proADM had a high accu-
racy in identifying both 28-day and 90-day mortality, 
compared to all other biomarkers and clinical scores, 
although many differences were not found to be sig-
nificant. Performance was maintained irrespective of 
whether the infection was developed in the community, 
culminating in a visit to the ED, or following a surgical 
procedure. Conversely, the SOFA score appeared to more 
accurately predict mortality in patients following a hos-
pital-acquired infection, although similarly, differences 
were not found to be significant. In each case, however, 
the small sample size and relatively low event rate result 
in few significant differences between biomarkers and 
scores, as highlighted when comparing 95% confidence 
intervals. Nevertheless, similar findings have been shown 
elsewhere. Elke et al. [25] previously found differences in 
performance depending on whether the infecting agent 
consisted solely of Gram positive vs. negative bacteria, 
as well as highlighting the influence of prior surgical 
procedures in patients directly admitted onto the ICU. 
A further ICU study by Andaluz-Ojeda et  al. [2] in 326 
patients with severe sepsis or septic shock, as well as that 
of Enguix-Armada [30] in 388 patients with septic shock, 
also found MR-proADM to have the highest predic-
tive value compared to conventional biomarkers such as 
PCT, CRP and lactate, although interestingly, the greatest 
performance was found in patients with a lower degree 
of organ failure. Nevertheless, no subgroup analysis was 
performed in either study relating to location of infec-
tion development or prior surgical history. It is, however, 
interesting to note that similar results to these high sever-
ity, critical care investigations could be observed in our 
less severe cohort across three different hospital depart-
ments. Accordingly, a significant body of evidence now 
appears to have been formed across all hospital depart-
ments, highlighting the use of MR-proADM in identify-
ing the patients at risk of mid- and long-term mortality.
In contrast, few studies have assessed MR-proADM 
performance in identifying patients requiring ICU 
admission. An early recognition of such patients is cru-
cial, since it has previously been shown that inappropri-
ate ED discharge can result in higher mortality rates in 
patients initially classified as suitable for outpatient treat-
ment, but later directly admitted onto the ICU. Simi-
lar findings were also reported after initial triage onto 
a medical ward [31]. The relatively high performance of 
MR-proADM in identifying these patients after presenta-
tion to the ED, with a modest performance during treat-
ment on a medical ward, may provide clinicians with an 
additional tool in assessing suitability for ICU admission. 
Nevertheless, further observational and interventional 
studies are required to confirm these initial findings, and 
determine the actual clinical value compared to standard 
routine practice.
We note several limitations and strengths of this study 
that deserve greater discussion. This was a single-cen-
tre pilot study with a relatively low number of enrolled 
patients, resulting in many subgroups being underpow-
ered for their respective endpoints. Results must there-
fore be treated with caution. Nevertheless, similar results 
were found in comparison to those previously discussed 
in the literature, despite the patient population enrolled 
in this study being preselected on the basis of fulfilling 
an in-house sepsis criteria, and can therefore be viewed 
as additional collaborative evidence. Similarly, the num-
ber of patients where the in-hospital sepsis code was 
activated, yet no infection was subsequently found, only 
amounted to 18 (12.2%) patients. A greater degree of 
confidence in the discriminatory results between infected 
and non-infected patients could be achieved with a larger 
sample size. Finally, biomarker incorporation within a 
sepsis code requires a short turnaround time to result, 
which may be achieved using point-of-care (POC) tech-
nology. At this point in time, however, no such platform 
exists for the measurement of MR-proADM, making rou-
tine incorporation of this biomarker in a clinical setting 
problematic.
Conclusions
This study found that the use of PCT to discriminate 
between infected and non-infected cases following activa-
tion of an in-hospital sepsis code, followed by measure-
ment of MR-proADM to determine infection severity and 
assess the requirement for ICU admission, may help guide 
initial treatment decisions and intensify therapy in high-
risk patients. Interventional studies, specifically focussing 
on MR-proADM, to potentially optimise early patient 
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treatment strategies are now crucial before implementation 
in routine clinical use.
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